• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

    4/17/25 8:30:00 AM ET
    $AKYA
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email

    Urges Shareholders to Vote AGAINST Both Proposals Related to the Value-Destructive Merger with Akoya at the Upcoming Special Meeting

    Notes Deeply Unfair Merger is Effectively a Bailout for Akoya at the Expense of Quanterix Shareholders

    Outlines Concerns Around Fundamentally Flawed Transaction Process and Conflicts of Interest Among Quanterix Board Members

    Visit www.SaveQTRX.com to Learn How to Vote the GOLD Proxy Card and Preserve Quanterix's Clear and Compelling Path Toward Long-Term Value Creation

    Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") and sent a letter to its fellow Quanterix shareholders in connection with its opposition to the Company's proposed merger (the "Merger") with Akoya Biosciences ("Akoya") (NASDAQ:AKYA).

    The full text of Kent Lake's letter can be found here: https://bit.ly/4ly8pZl

    Kent Lake urges shareholders to vote AGAINST both proposals related to the value-destructive Merger with Akoya on the GOLD proxy card at the upcoming special meeting of shareholders (the "Special Meeting") scheduled for May 13, 2025.

    For more information on how to vote and other relevant resources, shareholders are encouraged to visit www.SaveQTRX.com.

    If you have any questions, require assistance in voting your GOLD proxy card, or need additional copies of Kent Lake's proxy materials, please contact:

    Saratoga Proxy Consulting LLC

    520 8th Avenue

    New York, NY 10018

    Stockholders call toll-free at (888) 368-0379

    Email: [email protected]

    About Kent Lake

    Kent Lake Partners LP is an investment fund founded by Ben Natter in 2019 with a focus on small and mid-capitalization public equities, particularly in the healthcare space. Mr. Natter has over a decade of successful public healthcare equity investing experience.

    Certain Information Concerning the Participants

    Kent Lake Partners LP ("Kent Lake Partners") has filed a definitive proxy statement and accompanying GOLD proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes in connection with its opposition to proposals to be presented at a special meeting of stockholders (the "Special Meeting") of Quanterix Corporation, a Delaware corporation (the "Company"), in connection with the Company's agreement and plan of merger (the "Merger") with Akoya Biosciences, Inc. Kent Lake Partners, together with the other Participants (as defined below), also intends to file a preliminary proxy statement and accompanying GOLD universal proxy card with the SEC to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of the Company (the "Annual Meeting").

    KENT LAKE STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation against the Merger in connection with the Special Meeting are anticipated to be Kent Lake Partners, Kent Lake PR LLC ("Kent Lake PR") and Benjamin Natter (collectively, the "Kent Lake Parties"). The participants in the proxy solicitation in connection with the Annual Meeting are anticipated to be the Kent Lake Parties and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the "Kent Lake Nominees" and collectively with the Kent Lake Parties, the "Participants").

    As of the date hereof, Kent Lake Partners directly beneficially owned 3,001,000 shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock"). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 3,001,000 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 3,001,000 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250416213804/en/

    Investor Contacts

    Ben Natter, 415-237-0007

    [email protected]

    Saratoga Proxy Consulting LLC

    John Ferguson / Ann Marie Mellone

    212-257-1311 / 888-368-0379

    [email protected]

    Media Contact

    Longacre Square Partners

    Joe Germani / Kendall Heebink

    [email protected]

    Get the next $AKYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKYA
    $QTRX

    CompanyDatePrice TargetRatingAnalyst
    Akoya BioSciences Inc.
    $AKYA
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Buy → Neutral
    BTIG Research
    Akoya BioSciences Inc.
    $AKYA
    8/6/2024Overweight → Neutral
    JP Morgan
    Akoya BioSciences Inc.
    $AKYA
    6/21/2024$7.50Buy
    Craig Hallum
    Quanterix Corporation
    $QTRX
    2/1/2024$30.00Sector Outperform
    Scotiabank
    Akoya BioSciences Inc.
    $AKYA
    12/14/2023Neutral
    Guggenheim
    Quanterix Corporation
    $QTRX
    9/25/2023$25.00 → $32.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $AKYA
    $QTRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

      Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. ("EMISSION"). Quanterix expects the transaction will close in January 2025. "As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components," said Masoud Toloue, Chief Executive Officer of Quanterix. "EMISSION's proprietary bead technology has already been validated on our upcoming new Simoa platform and will en

      12/17/24 6:59:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis

      10/2/24 4:00:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Toloue Masoud covered exercise/tax liability with 254 shares, decreasing direct ownership by 0.05% to 474,518 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      5/2/25 4:05:19 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Sriram Vandana covered exercise/tax liability with 229 shares, decreasing direct ownership by 0.27% to 83,966 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      4/17/25 4:01:34 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud covered exercise/tax liability with 1,242 shares, decreasing direct ownership by 0.26% to 474,772 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      4/17/25 4:01:12 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation

      SCHEDULE 13G/A - Quanterix Corp (0001503274) (Subject)

      5/14/25 5:10:53 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Quanterix Corp (0001503274) (Filer)

      5/14/25 4:33:56 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Akoya BioSciences Inc.

      10-Q - Akoya Biosciences, Inc. (0001711933) (Filer)

      5/12/25 7:43:33 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Quanterix Corporation

      SC 13G/A - Quanterix Corp (0001503274) (Subject)

      11/13/24 12:41:46 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Walt David R bought $624,630 worth of shares (47,000 units at $13.29) and gifted 2,000 shares, increasing direct ownership by 3% to 1,487,342 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      9/17/24 4:35:10 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President & CEO Toloue Masoud bought $207,100 worth of shares (19,000 units at $10.90), increasing direct ownership by 6% to 354,119 units (SEC Form 4)

      4 - Quanterix Corp (0001503274) (Issuer)

      8/15/24 4:03:35 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    $QTRX
    Financials

    Live finance-specific insights

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix Releases Financial Results for the First Quarter of 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward," said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new early-access program, Simoa® ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide—significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by

      5/12/25 4:01:00 PM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

      Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To listen to the live conference call, investors can dial (800) 715-9871 or (646) 307-1963 and enter conference ID 7353673. Interested investors can also access the live we

      5/5/25 7:00:00 AM ET
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials